<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19635" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Clostridium botulinum Infection(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tiwari</surname>
            <given-names>Aman</given-names>
          </name>
          <aff>Sharda University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aman Tiwari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19635.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Clostridium</italic> is among the largest bacterial genera, belonging to the&#x000a0;Firmicutes&#x000a0;phylum.<xref ref-type="bibr" rid="article-19635.r1">[1]</xref><xref ref-type="bibr" rid="article-19635.r2">[2]</xref>&#x000a0;<italic toggle="yes">Clostridia</italic> are gram-positive, endospore-forming, obligate anaerobic bacilli that form exotoxins. They are ubiquitous in the environment and can also be found in humans and animals.&#x000a0;<xref ref-type="bibr" rid="article-19635.r2">[2]</xref>&#x000a0;<italic toggle="yes">Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Clostridium difficile, </italic>and<italic toggle="yes"> Clostridium sordellii a</italic>re commonly encountered clostridial species.<xref ref-type="bibr" rid="article-19635.r2">[2]</xref>&#x000a0;This activity focuses on <italic toggle="yes">Clostridium botulinum</italic>,&#x000a0;which produces botulinum neurotoxin, the most potent biologically-known substance that is the cause of botulism. Botulism is a neuroparalytic syndrome of reversible, symmetrical flaccid paralysis,&#x000a0;and although rare, this infection can lead to respiratory failure and death. Due to its potential fatality and the fact that it can be mistaken for other similar syndromes, the diagnosis can be difficult or missed. <xref ref-type="bibr" rid="article-19635.r3">[3]</xref>&#x000a0;Clinicians should have a high index of suspicion for <italic toggle="yes">Clostridium botulinum</italic> infection when evaluating patients to diagnose and treat it promptly.</p>
      </sec>
      <sec id="article-19635.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">Clostridium botulinum</italic> belongs to the genus<italic toggle="yes"> Clostridium,</italic>&#x000a0;which is among the largest bacterial genera and belongs to the&#x000a0;Firmicutes&#x000a0;phylum.<xref ref-type="bibr" rid="article-19635.r1">[1]</xref><xref ref-type="bibr" rid="article-19635.r2">[2]</xref>&#x000a0;<italic toggle="yes">Clostridia</italic> are gram-positive, spore-forming, obligate anaerobic bacilli that form exotoxins.<xref ref-type="bibr" rid="article-19635.r2">[2]</xref>&#x000a0;<italic toggle="yes">C botulinum</italic> is ubiquitous in the environment and is found as a saprophyte in soil, animal manure, vegetables, and sea mud.<xref ref-type="bibr" rid="article-19635.r4">[4]</xref>&#x000a0; The neurotoxin produced by this organism has likely evolved for it to acquire nutrition by killing its host.&#x000a0;Botulism derives from the Latin "<italic toggle="yes">botulus,"</italic>&#x000a0;which means "sausage," because it was originally&#x000a0;associated with&#x000a0;contaminated&#x000a0;sausages in Germany.<xref ref-type="bibr" rid="article-19635.r5">[5]</xref></p>
        <p><italic toggle="yes">C botulinum </italic>produces&#x000a0;botulinum neurotoxin (BoNT), which is responsible for most cases of botulism. <italic toggle="yes">C botulinum</italic> produces 7 immunologically different toxins, and they are designated using letters from A to G.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref> Most&#x000a0;of the cases of foodborne botulism worldwide are caused by BoNT type A, B, E, and F. Botulism is a potentially fatal paralytic illness that manifests as a descending flaccid, symmetrical paralysis and can lead to respiratory failure and death. Clostridial BoNT, considered the most potent neurotoxin, is a zinc metalloprotease that blocks the exocytosis of cholinergic neurotransmitters at the neuromuscular junctions, thus resulting in flaccid paralysis.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r6">[6]</xref>&#x000a0;The exact lethal dose of BoNT is not known; a commonly cited estimated lethal dose of toxin type A is 0.09 to 0.15 &#x003bc;g intravenous and 0.8 to 0.9 &#x003bc;g inhaled. Lower doses have also been reported.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref></p>
        <p>Botulism can occur in 3 forms, depending on the route of entry: foodborne, wound botulism, infant botulism, adult intestinal botulism, and iatrogenic botulism. Endospores of <italic toggle="yes">C botulinum</italic> are ubiquitous in the environment, and ingestion of spores occurs through contact with the environment. They are routinely ingested and excreted from the human intestine without germination, and thus, there is no toxin production and no clinical disease. If the intestine is anatomically compromised or its microbiome is compromised, endospores may find an appropriate environment and germinate, causing intestinal botulism.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r7">[7]</xref></p>
        <p>When appropriate hygienic and sterilization conditions are implemented during the manufacturing of commercially processed products, botulism rarely ensues.&#x000a0;Botulism can occur when there are deficiencies in the manufacturing of such products, which allows the food to be contaminated&#x000a0;with already produced BoNT and/or <italic toggle="yes">C botulinum</italic> endospores, which can produce BoNT.<xref ref-type="bibr" rid="article-19635.r8">[8]</xref><italic toggle="yes">&#x000a0;</italic>Metabolically dormant endospores of<italic toggle="yes"> C botulinum, </italic>which are anaerobic,&#x000a0;cause disease.<xref ref-type="bibr" rid="article-19635.r9">[9]</xref> The endospores are ubiquitous and resistant to high temperatures, enzyme digestion, and pressure changes.<xref ref-type="bibr" rid="article-19635.r10">[10]</xref> Thus, the presence of the endospore in foods, with conditions of poor sterilization and processing, leads to anaerobic environments that allow <italic toggle="yes">C botulinum</italic> to germinate and form BoNT.<xref ref-type="bibr" rid="article-19635.r9">[9]</xref> Such conditions can occur during home canning, which leads&#x000a0;to&#x000a0;toxin-producing vegetative cells that intoxicate the food.<xref ref-type="bibr" rid="article-19635.r9">[9]</xref></p>
        <p>Foodborne botulism&#x000a0;occurs when preformed BoNT is ingested directly from food. The BoNT is produced by cells that originate from endospores that have germinated. Homemade canned food is the most common source of foodborne botulism; most cases are sporadic, and outbreaks are rare. In addition to the flaccid, symmetrical paralysis, gastrointestinal symptoms may also be noted. Wound botulism occurs when spores enter a wound, germinate, and produce toxins.&#x000a0;The clinical presentation is&#x000a0;similar to foodborne botulism but without the gastrointestinal symptoms.<xref ref-type="bibr" rid="article-19635.r6">[6]</xref>&#x000a0;Intestinal botulism occurs in patients with anatomically compromised intestines or dysbiosis when colonized with neurotoxigenic <italic toggle="yes">C botulinum; </italic>the organism<italic toggle="yes">&#x000a0;</italic>can&#x000a0;germinate and produce BoNT in their intestines.&#x000a0;Intestinal botulism&#x000a0;is called infant botulism if the person is under one year&#x000a0;of age, and if the patient is older than one year of age, it is called adult intestinal botulism.&#x000a0;Infant botulism from ingesting contaminated food (usually honey) with spores of <italic toggle="yes">C botulinum.</italic><xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r7">[7]</xref> Clinical manifestations&#x000a0;include the inability to suck and swallow, a weak voice, ptosis, a floppy neck, and extreme weakness and hence referred to as "floppy baby syndrome." This is a self-limiting condition, managed by supportive care and assisted feeding.&#x000a0;Rarely,&#x000a0;it can progress to generalized flaccidity, respiratory failure, and sudden death. Symptoms of all types of botulism are similar and involve symmetrical, flaccid paralysis, except for foodborne botulism, when gastrointestinal symptoms (eg, diarrhea) may occur before the neurological symptoms.<xref ref-type="bibr" rid="article-19635.r6">[6]</xref></p>
      </sec>
      <sec id="article-19635.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Generally, in countries with adequate resources and an excellent public health system, botulism is a notifiable disease, and data on incidence, trends, and mortality have been reported. Published data show that the incidence of human botulism has markedly decreased worldwide, as has mortality; this is most likely because of improved clinical recognition and diagnosis, treatment options, including the use of botulism antitoxin, and improved food safety measures and standards. A systematic review published in 2015 identified 197 outbreaks of foodborne botulism from 1920 to 2014.<xref ref-type="bibr" rid="article-19635.r11">[11]</xref> The most commonly implicated cause of botulism were&#x000a0;toxin types A, B, E, and F in 34%, 16%, 17%, and 1% of outbreaks, respectively.<xref ref-type="bibr" rid="article-19635.r11">[11]</xref>&#x000a0;Outbreaks were reported from 27 countries, and the majority&#x000a0;of outbreaks, 55%, occurred in the United States, followed by Canada at 15%, Europe at 13%, Asia at 13%, Africa at 3% and Australia at 2%.<xref ref-type="bibr" rid="article-19635.r11">[11]</xref>&#x000a0;Most cases in the United States were due to home-canning of foods; in Europe, they were primarily due to commercial foods. Toxin A was the cause of 58% of the outbreaks in the United States, 45% in Europe, and 50% in Asia,&#x000a0;whereas toxin type E was responsible for 50% of Canadian outbreaks. The incubation period was shorter in toxin type E botulism than in cases caused by toxin A; case-patients involving type A toxin had the highest mean percentage of mechanical ventilation, and mortality was lower for outbreaks in which all cases with toxin A and E botulism had received matching antitoxin (7.8% vs 53.9%;&#x000a0;<italic toggle="yes">P</italic>&#x000a0;&#x0003c; .001).<xref ref-type="bibr" rid="article-19635.r11">[11]</xref>&#x000a0;These findings are consistent with other reports.<xref ref-type="bibr" rid="article-19635.r12">[12]</xref></p>
        <p>The&#x000a0;United States&#x000a0;Center for Disease Control and Prevention has been monitoring cases of botulism in the United States since 1973. From 2011 through 2015, an average of 162 annual cases were reported. These primarily included infant botulism at 71% to 88%, followed by foodborne botulism, wound botulism, and botulism of unknown origin. Botulism cases have remained relatively stable over the past 10 years except for rare, large outbreaks.<xref ref-type="bibr" rid="article-19635.r13">[13]</xref><xref ref-type="bibr" rid="article-19635.r14">[14]</xref>&#x000a0;The mortality rate had decreased significantly from over 60% in the 1950s to only 3% in 2009, mostly likely due to appropriate detection,&#x000a0;better supportive care, and the development of botulinum antitoxin.<xref ref-type="bibr" rid="article-19635.r15">[15]</xref> Most deaths reported are due to cases of botulism without a known source, followed by foodborne, wound, and infant botulism, which comprise less than 1% of cases.<xref ref-type="bibr" rid="article-19635.r16">[16]</xref></p>
        <p>A 2023 report from Canada has&#x000a0;documented 55 cases of foodborne botulism from 2006 until 2021.<xref ref-type="bibr" rid="article-19635.r17">[17]</xref>&#x000a0;The&#x000a0;mean annual incidence was 0.01 cases per 100,000 individuals. Botulinum toxin E&#x000a0;was identified as the cause in 52% of cases, type A was responsible in 24%, type B in 16%, type F in 3%, and type AB in 1%. Seventy percent of cases required mechanical ventilation, and 7 deaths were reported. Type A toxin was responsible for longer hospital stays.<xref ref-type="bibr" rid="article-19635.r17">[17]</xref>&#x000a0;</p>
        <p>Results from an epidemiological study from Taiwan reported 50 cases of botulism between 2003 and 2020, with an incidence ranging from 0 to 0.48 per 1000,000 from 2003 to 2020 and an overall decreasing trend.<xref ref-type="bibr" rid="article-19635.r8">[8]</xref>&#x000a0;Most of the patients were women (56%), were 50 years old or older, and lived in Taipei and northern Taiwan (44%). From 2010 to 2020, however, botulism in children &#x000a0;youtnger than 20 showed an increasing trend, and&#x000a0;most of the children were boys (66.7%). Infections mainly occurred during the spring and summer months (66.7%).<xref ref-type="bibr" rid="article-19635.r8">[8]</xref>&#x000a0;Data from 2015 and 2022 from the European Centre for Disease Prevention and Control report a stable number of cases of botulism in Europe at &#x000a0;less than 0.1 cases per 100,000 individuals. Infant botulism, defined as children younger than 1, was&#x000a0;the group with the highest rate of botulism.<xref ref-type="bibr" rid="article-19635.r18">[18]</xref></p>
      </sec>
      <sec id="article-19635.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Humans can ingest spores that pass through the intestine without germinating; the toxin is produced only when spores germinate. Most&#x000a0;of the cases of foodborne botulism worldwide are caused by BoNT type A, B, E, and F. Toxin type A causes the most severe botulism, and most patients with this toxin require mechanical ventilation.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref> Botulism is a potentially fatal paralytic illness that manifests as a descending flaccid, symmetrical paralysis and can lead to respiratory failure and death. Botulinum toxin can, however, also be used for therapeutic reasons because it causes flaccid paralysis; aesthetic and medical conditions that BoNT can treat include strabismus, blepharospasm, chronic migraines, torticollis, hyperhidrosis,&#x000a0;and myoclonus.<xref ref-type="bibr" rid="article-19635.r20">[20]</xref>&#x000a0;</p>
        <p><italic toggle="yes">C botulinum&#x000a0;</italic>produces&#x000a0;botulinum neurotoxin (BoNT), a zinc-dependent protein of 150 kDa (100 kDa heavy chain and a 50 kDa light chain), and is responsible for most cases of botulism.&#x000a0;<italic toggle="yes">C botulinum</italic>&#x000a0;produces 7 immunologically different toxins, and they are designated using letters from A to G, some with subtypes (A, B, C1, C2, D, E, F, and G ) based on the immunological differences in the toxins they produce. All serotypes produce neurotoxin, except C2, which produces an enterotoxin.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r20">[20]</xref> BoNT types C and D are bacteriophage-coded. Botulinum neurotoxin differs from other exotoxins as it&#x000a0;is produced intracellularly, is not secreted, and appears outside only after bacterial cell autolysis. The toxin is synthesized initially as a nontoxic protoxin; this requires trypsin or other proteolytic enzymes to convert it into an active form.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref>&#x000a0;Clostridial BoNT, considered the most potent neurotoxin, is a zinc metalloprotease that blocks the exocytosis of cholinergic neurotransmitters at the neuromuscular junctions, thus resulting in flaccid paralysis.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r6">[6]</xref>&#x000a0;The exact lethal dose of BoNT is not known; a commonly cited estimated lethal dose of toxin type A is 0.09 to 0.15 &#x003bc;g intravenously and 0.8 to 0.9 &#x003bc;g inhaled. Lower doses have also been reported.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref></p>
        <p>The BoNT is absorbed into the bloodstream from either a foodborne, wound, intestinal,&#x000a0; or inhalational exposure and moves to the peripheral cholinergic nerve terminals, which include the neuromuscular junctions, postganglionic parasympathetic nerve endings,&#x000a0;and peripheral ganglia.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref>&#x000a0;The&#x000a0;BoNT binds to the neuron, is internalized by endocytosis, and moves to the cytosol. Then it cleaves the proteins that release acetylcholine at the nerve junctions, and by inhibiting the release of acetylcholine, it blocks the transmission of the neurotransmitter across the junction, resulting in flaccid paralysis. BoNT&#x000a0;does not cross the blood-brain barrier; the BoNT binds irreversibly to the nerve terminal, and recovery only occurs when new nerve terminals have sprouted. This process may take weeks to months.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref></p>
      </sec>
      <sec id="article-19635.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Botulism is a potentially life-threatening paralytic illness, and clinicians must, therefore, have a high index of suspicion when evaluating patients. Early clinical diagnosis of botulism is essential because the paralysis can quickly result in respiratory failure, and the antitoxin should be given as soon as possible. A&#x000a0;complete travel, exposure, and risk factor history is essential to evaluate the possibility of ingestion or contamination of <italic toggle="yes">C botulinum</italic> spores or toxins. Such exposures include ingestion of improperly canned, preserved, or fermented foods, use of injectable drugs (particularly black-tar heroin), recent surgical procedures or injections,&#x000a0;occurrence of contaminated wounds, ingestion of honey, any environmental exposure to soil containing <italic toggle="yes">C botulinu</italic>m endospores, and having received a large dose of BoNT for therapeutic or cosmetic purposes.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r21">[21]</xref></p>
        <p>Symptoms of botulism can occur suddenly and usually appear 12 to 36 hours after exposure to the BoNT, although they can range from a few hours to a few days.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref>&#x000a0;An extensive systematic review&#x000a0;by Chatham-Stephens et al identified 233 studies and 171 patients with botulism with available data on foodborne and wound botulism clinical features from 1935 to 2015.<xref ref-type="bibr" rid="article-19635.r22">[22]</xref>&#x000a0;The median incubation period was 1 day, and the shortest reported was 2 hours.<xref ref-type="bibr" rid="article-19635.r22">[22]</xref></p>
        <p>The clinical presentation of botulism is&#x000a0;classic and follows a familiar pattern in most patients. Patients can appear weak and fatigued, and symptoms and signs usually start from the cranial nerves and then follow a descending, symmetrical paralysis of the torso and extremities with areflexia. Shortness of breath, tachypnea, or the inability to use respiratory muscles may be observed in patients with impending respiratory failure. Cranial nerve involvement can present as diplopia, ptosis, facial palsy, dysphagia, dysarthria, dysphonia, ophthalmoplegia with blurry vision, impaired gag reflex, and neck weakness. The most common signs are descending paralysis, ptosis, and ophthalmoplegia. The "4 Ds" are a mnemonic for cranial nerve paralysis: dysphagia, dysarthria, dry mouth, and diplopia.<xref ref-type="bibr" rid="article-19635.r22">[22]</xref>&#x000a0;Clinical criteria have been proposed by Rao et al to "trigger suspicion for botulism" so that rapid diagnosis and treatment can be performed.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref><xref ref-type="bibr" rid="article-19635.r23">[23]</xref></p>
        <p>Nausea, vomiting, and abdominal pain are commonly reported in patients with foodborne botulism, and these symptoms can occur even before any neurological symptoms and signs appear. Constipation is a nearly universal eventual symptom.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r22">[22]</xref>&#x000a0;Descending flaccid, symmetrical paralysis of voluntary muscles can follow the cranial nerve palsies, although in some cases, patients may only have cranial palsy-limited symptoms.&#x000a0;Botulism usually descends, affecting neck, shoulders, torso, and proximal muscles before the distal extremities. This distribution is related to the toxins circulating through the body via the bloodstream after absorption.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref></p>
      </sec>
      <sec id="article-19635.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinicians should be aware that the clinical course of a patient with botulism can evolve rapidly, and botulism should be included in the differential diagnosis to provide immediate supportive care and administer antitoxin. Clinical criteria have been proposed by Rao et al to "trigger suspicion for botulism" so that rapid diagnosis and treatment can be performed.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref><xref ref-type="bibr" rid="article-19635.r23">[23]</xref>&#x000a0;Respiratory failure may occur not only because of paralysis of respiratory muscles but also&#x000a0;because of cranial nerve paresis with&#x000a0;pharyngeal collapse.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref>&#x000a0;Botulism should be considered in any patient in whom Guillain-Barre or myasthenia gravis is suspected, and serial neurological examinations should be performed.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref>&#x000a0;Isolated cases can be missed because the diagnosis may not be considered. Still, if the evaluation is performed with a high index of suspicion, the clinical diagnosis can be made, pending the laboratory results. If more than 2 patients have similar symptoms, the diagnosis of botulism is almost pathognomonic&#x000a0;because the other diseases that may be confused with botulism do not produce outbreaks.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref>&#x000a0;General laboratory tests, cerebrospinal fluid analysis, and neuroimaging are usually normal. Laboratory confirmation can be performed by detecting BoNT in serum, stool, or food or by culturing the organism. However, laboratory testing may take hours or days, so the clinical diagnosis through a complete history and physical examination&#x000a0;is essential.&#x000a0;</p>
        <p>When clinicians see patients, a high index of suspicion is essential. Thinking of other syndromes that this condition may mimic and to be able to differentiate them as best as possible with whatever methods are available in most hospitals is crucial. Myasthenia gravis, Guillain-Barre, and cerebrovascular accidents are syndromes requiring special mention. Cerebrospinal fluid analysis is normal in botulism but abnormal in Guillain-Barre syndrome. The edrophonium test would be positive in myasthenia gravis but normal in botulism. Electromyography and nerve conduction studies&#x000a0;could help differentiate botulism from other etiologies of motor neuron conduction diseases. However,&#x000a0;not all healthcare systems have such equipment; these tests are operator-dependent and require expert interpretation. They also may not be positive early in the course of the disease.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref></p>
        <p>The&#x000a0;diagnosis of botulism can be confirmed by detecting the BoNT in serum, feces, any other sample, and food. Identification of <italic toggle="yes">C botulinum</italic> in vomitus, gastric secretions, stool, or wound samples is diagnostic for infant botulism and adequate for adult botulism, always in conjunction with the clinical picture. The gold standard method to detect the BoNT is the mouse bioassay, which is available in only a few laboratories and requires having a population of mice on which to test. A specimen sample is injected into the peritoneum of a mouse, and the mouse is monitored for paralysis for up to 96 hours. However, paralysis&#x000a0;is usually observed&#x000a0;in the first 48 hours.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r19">[19]</xref>&#x000a0;Other methods, but only available at reference laboratories, is the real-time polymerase chain reaction test that&#x000a0;detects&#x000a0;<italic toggle="yes">bont </italic>genes A to G and can identify clostridial species from cultures and the mass spectrometry method for detecting BoNT.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref></p>
        <p>Administrating antitoxin before the injection of the sample in the mouse bioassay can prevent paralysis in the mouse. The sensitivity of the mouse bioassay varies inversely with the time elapsed between the onset of symptoms and sample collection and has been reported to be as low as 33% to 44%.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref><xref ref-type="bibr" rid="article-19635.r24">[24]</xref>&#x000a0;When&#x000a0;botulism, other than infant botulism, is suspected,&#x000a0;samples should be obtained before the antitoxin is given because&#x000a0;the antitoxin can neutralize circulating BoNT, and detection may be difficult. Generally, the presence of toxin is more diagnostic of botulism than the detection of<italic toggle="yes"> C botulinum </italic>by Gram stain and culture. Detection of the organisms by culture can be adequate when considering the characteristic clinical picture. Every case of botulism is a public health emergency and should be reported to the public health department. The public health department should start an epidemiological investigation to identify the source of the infection and find other persons who may have been exposed.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref></p>
      </sec>
      <sec id="article-19635.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Evaluation, diagnosis, and treatment should be done rapidly to ensure the best possible outcomes for patients, especially since botulism can be a rapidly progressing disease. Supportive care and antitoxin administration are the quintessential components of treatment for botulism. Patients with acute-onset flaccid paralysis from botulism should be admitted to the hospital and intensive care unit and should be monitored regularly. If there is impending respiratory failure, intubation and mechanical ventilation may be necessary.<xref ref-type="bibr" rid="article-19635.r3">[3]</xref></p>
        <p>Antitoxin should be administered right away, even with only a clinical diagnosis, and laboratory confirmation is not necessary, as it is a lengthy process, and immediate treatment is necessary. The antitoxin should be given within the first 24 hours of symptoms. When antitoxin is administered&#x000a0;sooner rather than later, patient outcomes&#x000a0;are improved because the antitoxin neutralizes unbound free BoNT.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref>&#x000a0;If the botulism is caused by wound botulism, wounds should be cleaned and debrided promptly, and antibiotics should be administered, if necessary.<xref ref-type="bibr" rid="article-19635.r25">[25]</xref><xref ref-type="bibr" rid="article-19635.r26">[26]</xref></p>
        <p>Mortality from botulism has markedly decreased from 60% to 70% at the beginning of the century to the current rate of 3% to 5%. This is most likely due to many factors, including increased awareness and faster diagnosis, more evolved intensive care methods, including mechanical ventilation, and the administration of antitoxin.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref>&#x000a0;The BoNT binds irreversibly to the presynaptic cholinergic nerve terminals, and recovery occurs when new&#x000a0;axon terminals are generated. Supportive physical therapy and possibly long-term rehabilitation may be necessary to fully recover functionality.</p>
      </sec>
      <sec id="article-19635.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The conditions that can mimic <italic toggle="yes">Clostridium botulism</italic> are as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Guillain-Barre syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cerebral Vascular Accident&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Poliomyelitis</p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis</p>
          </list-item>
          <list-item>
            <p>Amyotrophic lateral sclerosis</p>
          </list-item>
          <list-item>
            <p>Lambert Eaton syndrome</p>
          </list-item>
          <list-item>
            <p>Tick paralysis</p>
          </list-item>
          <list-item>
            <p>Acute intermittent porphyria&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Shellfish poisoning</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19635.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Generally, when patients are evaluated, diagnosed, and treated promptly, the prognosis of botulism is excellent,&#x000a0;and a full recovery is expected. Timely evaluation and diagnosis&#x000a0;of patients with botulism is essential so they can receive supportive care and antitoxin quickly. If respiratory muscles are affected, intubation and mechanical ventilation may be necessary. A survival analysis&#x000a0;from an outbreak of botulism in Thailand reported that from the 91 patients who were hospitalized with botulism, all of whom had received antitoxin, 42 required mechanical ventilation, the median time on the ventilator was 14 days, mechanical ventilation was associated with a shorter incubation and pupillary abnormalities, and there were no deaths.<xref ref-type="bibr" rid="article-19635.r27">[27]</xref>&#x000a0;</p>
        <p>Almost all patients can survive, even without the antitoxin, as long as they receive supportive care, including mechanical ventilation.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref> Mortality from botulism has markedly decreased from 60% to 70% at the beginning of the century to the current rate of 3% to 5%. This decrease is most likely due to many factors, including increased awareness and faster diagnosis, more evolved intensive care methods, including mechanical ventilation, and the administration of antitoxin.<xref ref-type="bibr" rid="article-19635.r19">[19]</xref></p>
      </sec>
      <sec id="article-19635.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Complications from&#x000a0;<italic toggle="yes">Clostridium botulism </italic>infection can include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nosocomial infections</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection</p>
          </list-item>
          <list-item>
            <p>Thrombophlebitis</p>
          </list-item>
          <list-item>
            <p>Deep vein thrombosis</p>
          </list-item>
          <list-item>
            <p>Pressure sores</p>
          </list-item>
          <list-item>
            <p>Contractures</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19635.s11" sec-type="Consultations">
        <title>Consultations</title>
        <p>Due to the potentially severe clinical syndrome caused by botulism with the need for hospitalization and the possibility&#x000a0;of respiratory failure and death, it is essential to quickly make the diagnosis&#x000a0;and treat patients. Treatment consists of supportive care, mechanical ventilation, if necessary, and the administration of antitoxin. Consulting medical specialties that are pertinent not only to the initial disease but also to the patient's projected clinical needs may be pertinent. Such medical consultations include neurologists, infectious disease specialists, and intensive care physicians. Other specialties that would be required include physical medicine and rehabilitation physicians who work in conjunction with physical therapists.</p>
      </sec>
      <sec id="article-19635.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Proper canning, strict adherence to hygiene, and sterilization techniques are recommended. To avoid infant botulism, children younger than 2 should not be given honey.&#x000a0;</p>
      </sec>
      <sec id="article-19635.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>As most cases of botulism follow the consumption of inadequately canned or preserved food, control is achievable by proper canning and preservation. When an outbreak occurs, a prophylactic dose of antitoxin should be given intramuscularly to all who consumed the food article.</p>
      </sec>
      <sec id="article-19635.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with botulism are at high&#x000a0;risk of rapid-onset flaccid paralysis and respiratory failure. Early identification and management of botulism cases are imperative in reducing morbidity and mortality. Caring for patients with&#x000a0;botulism&#x000a0;necessitates a collaborative approach among healthcare professionals to ensure patient-centered care and improve overall outcomes. Neurologists, emergency medicine physicians, critical care physicians, infectious disease physicians, advanced clinicians, nurses, pharmacists, and other healthcare professionals involved in the care of these patients should possess the essential clinical skills and knowledge to diagnose and manage botulism accurately.&#x000a0;</p>
        <p>A strategic approach is equally crucial, involving evidence-based strategies to optimize treatment plans and minimize&#x000a0;adverse effects. Ethical considerations must guide decision-making, ensuring informed consent while respecting patient autonomy in treatment choices. Each healthcare professional must be aware of their responsibilities and contribute their unique expertise to the patient's care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and their follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance when managing botulism.</p>
      </sec>
      <sec id="article-19635.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19635&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19635">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/clostridium-botulinum-infection-botulism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19635">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19635/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19635">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19635.s16">
        <fig id="article-19635.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Botulinum Toxin Injections for Blepharospasm. Botulinum toxin injections may be administered at various sites, as depicted in the image. The dosage varies depending on the severity of the blepharospasm and apraxia of eyelid opening at each specific point. Pretarsal injections are administered to specifically counteract apraxia of eyelid opening. Injections just lateral to the lateral nasal wall aim to alleviate the squeezing of the nasalis muscle, which is observed in some patients. Injections into the corrugator and procerus muscles reduce the downward movement of the brow, consequently aiding eyelid control. Injections just below the brows provide a chemical lift to the brows, thereby improving the ability to open the eyelids. Caution is warranted to inject a minimal amount over the zygomaticus major and minor muscles to prevent the appearance of lower facial weakness following injections. Contributed by BCK Patel, MD, FRCS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Botox__injection__sites" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19635.s17">
        <title>References</title>
        <ref id="article-19635.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000fc;rre</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Physiology and Sporulation in Clostridium.</article-title>
            <source>Microbiol Spectr</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>TBS</fpage>
            <page-range>TBS-0010-2012</page-range>
            <pub-id pub-id-type="pmid">26104199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruz-Morales</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Orellana</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moutafis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moonen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rincon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Marcellin</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the Evolution and Taxonomy of Clostridia, a Phylogenomic Update.</article-title>
            <source>Genome Biol Evol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>2035</fpage>
            <page-range>2035-2044</page-range>
            <pub-id pub-id-type="pmid">31076745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Botulism.</article-title>
            <source>Clin Infect Dis</source>
            <year>2005</year>
            <month>Oct</month>
            <day>15</day>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>1167</fpage>
            <page-range>1167-73</page-range>
            <pub-id pub-id-type="pmid">16163636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickson</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Shevky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>BOTULISM. STUDIES ON THE MANNER IN WHICH THE TOXIN OF CLOSTRIDIUM BOTULINUM ACTS UPON THE BODY : II. THE EFFECT UPON THE VOLUNTARY NERVOUS SYSTEM.</article-title>
            <source>J Exp Med</source>
            <year>1923</year>
            <month>Sep</month>
            <day>30</day>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-46</page-range>
            <pub-id pub-id-type="pmid">19868794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torrens</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Clostridium botulinum was named because of association with "sausage poisoning.</article-title>
            <source>BMJ</source>
            <year>1998</year>
            <month>Jan</month>
            <day>10</day>
            <volume>316</volume>
            <issue>7125</issue>
            <fpage>151</fpage>
            <pub-id pub-id-type="pmid">9490126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dempster</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Minton</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Pathogenicity and virulence of <italic>Clostridium botulinum</italic>.</article-title>
            <source>Virulence</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>2205251</fpage>
            <pub-id pub-id-type="pmid">37157163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Anniballi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Adult Intestinal Toxemia Botulism.</article-title>
            <source>Toxins (Basel)</source>
            <year>2020</year>
            <month>Jan</month>
            <day>24</day>
            <volume>12</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">31991691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and risk factors for notifiable Clostridium botulinum infections in Taiwan from 2003 to 2020.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Oct</month>
            <day>21</day>
            <volume>101</volume>
            <issue>42</issue>
            <fpage>e31198</fpage>
            <pub-id pub-id-type="pmid">36281180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Sarker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Paredes-Sabja</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Sporulation and Germination in Clostridial Pathogens.</article-title>
            <source>Microbiol Spectr</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31858953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abecasis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quintais</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pereira-Leal</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Henriques</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>A genomic signature and the identification of new sporulation genes.</article-title>
            <source>J Bacteriol</source>
            <year>2013</year>
            <month>May</month>
            <volume>195</volume>
            <issue>9</issue>
            <fpage>2101</fpage>
            <page-range>2101-15</page-range>
            <pub-id pub-id-type="pmid">23396918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleck-Derderian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Chatham-Stephens</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adjei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Meaney-Delman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>The Epidemiology of Foodborne Botulism Outbreaks: A Systematic Review.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <day>27</day>
            <volume>66</volume>
            <issue>suppl_1</issue>
            <fpage>S73</fpage>
            <page-range>S73-S81</page-range>
            <pub-id pub-id-type="pmid">29293934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodruff</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>McCroskey</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Smart</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wainwright</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Hutwagner</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Hatheway</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988.</article-title>
            <source>J Infect Dis</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>166</volume>
            <issue>6</issue>
            <fpage>1281</fpage>
            <page-range>1281-6</page-range>
            <pub-id pub-id-type="pmid">1431246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czerwi&#x00144;ski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Czarkowski</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kondej</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Foodborne botulism in Poland in 2016.</article-title>
            <source>Przegl Epidemiol</source>
            <year>2018</year>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-155</page-range>
            <pub-id pub-id-type="pmid">30111083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mody</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Clinical Characteristics and Ancillary Test Results Among Patients With Botulism-United States, 2002-2015.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <day>27</day>
            <volume>66</volume>
            <issue>suppl_1</issue>
            <fpage>S4</fpage>
            <page-range>S4-S10</page-range>
            <pub-id pub-id-type="pmid">29293936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ni</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <chapter-title>Botulism Antitoxin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>9</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30521228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mahon</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fagan</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Botulism mortality in the USA, 1975-2009.</article-title>
            <source>Botulinum J</source>
            <year>2015</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-17</page-range>
            <pub-id pub-id-type="pmid">28603554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tchao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prystajecky</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weedmark</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tcholakov</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Foodborne Botulism, Canada, 2006-2021<sup>1</sup>.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>1730</fpage>
            <page-range>1730-7</page-range>
            <pub-id pub-id-type="pmid">37610295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pe&#x000f1;uelas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guerrero-Vadillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valdezate</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Leon-Gomez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Flores-Cu&#x000e9;llar</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Carrasco</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Garc&#x000ed;a</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Varela</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Botulism in Spain: Epidemiology and Outcomes of Antitoxin Treatment, 1997-2019.</article-title>
            <source>Toxins (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>20</day>
            <volume>15</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36668823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chatham-Stephens</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luquez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2021</year>
            <month>May</month>
            <day>07</day>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>1</fpage>
            <page-range>1-30</page-range>
            <pub-id pub-id-type="pmid">33956777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nigam</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Nigam</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Botulinum toxin.</article-title>
            <source>Indian J Dermatol</source>
            <year>2010</year>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">20418969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dhital</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Espinoza</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Jariwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Valdez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heidari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sabetian</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Wound Botulism in Black Tar Heroin Injecting Users: A Case Series.</article-title>
            <source>J Investig Med High Impact Case Rep</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>9</volume>
            <fpage>23247096211028078</fpage>
            <pub-id pub-id-type="pmid">34259080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatham-Stephens</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fleck-Derderian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Meaney-Delman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features of Foodborne and Wound Botulism: A Systematic Review of the Literature, 1932-2015.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <day>27</day>
            <volume>66</volume>
            <issue>suppl_1</issue>
            <fpage>S11</fpage>
            <page-range>S11-S16</page-range>
            <pub-id pub-id-type="pmid">29293923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Griese</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Chatham-Stephens</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Badell</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical Criteria to Trigger Suspicion for Botulism: An Evidence-Based Tool to Facilitate Timely Recognition of Suspected Cases During Sporadic Events and Outbreaks.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <day>27</day>
            <volume>66</volume>
            <issue>suppl_1</issue>
            <fpage>S38</fpage>
            <page-range>S38-S42</page-range>
            <pub-id pub-id-type="pmid">29293926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Mar&#x000e9;chal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fourour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ballan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rouxel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Souillard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chemaly</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Detection of Clostridium botulinum group III in environmental samples from farms by real-time PCR using four commercial DNA extraction kits.</article-title>
            <source>BMC Res Notes</source>
            <year>2018</year>
            <month>Jul</month>
            <day>04</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>441</fpage>
            <pub-id pub-id-type="pmid">29973253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Przedpelski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tepp</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Zuverink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Pellet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barbieri</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Enhancing toxin-based vaccines against botulism.</article-title>
            <source>Vaccine</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>827</fpage>
            <page-range>827-832</page-range>
            <pub-id pub-id-type="pmid">29307477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sobel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Making the Best of the Evidence: Toward National Clinical Guidelines for Botulism.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <day>27</day>
            <volume>66</volume>
            <issue>suppl_1</issue>
            <fpage>S1</fpage>
            <page-range>S1-S3</page-range>
            <pub-id pub-id-type="pmid">29293933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19635.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witoonpanich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vichayanrat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tantisiriwit</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wongtanate</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sucharitchan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oranrigsupak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chuesuwan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakarawat</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suwatcharangkoon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ingsathit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rattanasiri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wananukul</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Survival analysis for respiratory failure in patients with food-borne botulism.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-83</page-range>
            <pub-id pub-id-type="pmid">20184431</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
